Oncothyreon (ONTY) Clobbered on Stimuvax Interim Analysis
Tweet
Share
E-mailGet Alerts ONTY Hot Sheet
Join SI Premium – FREE
Shares of Oncothyreon Inc. (Nasdaq: ONTY) are under heavy pressure following disappointing interim analysis of cancer drug Stimuvax .
Partner Merck KGaA's will continue to final analysis, with final result expected in 2013.
Shares of Oncothyreon, which licensed the vaccine to Merck KGaA, is down 42 percent to $4.90 in pre-open trading Tuesday.
Partner Merck KGaA's will continue to final analysis, with final result expected in 2013.
Shares of Oncothyreon, which licensed the vaccine to Merck KGaA, is down 42 percent to $4.90 in pre-open trading Tuesday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- IBM tumbles on soft Q1 revenue; announces HashiCorp $6.4bn acquisition
- BHP Group (BHP) Said to Weigh Potential Takeover of Anglo American (NGLOY) - Bloomberg
- Analysts favorite fintech stock Adyen tumbles after revenue miss
Create E-mail Alert Related Categories
FDA, Hot FDA News, Momentum Movers, Trader TalkSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
